MX389073B - Método para producir una proteína de fusión de anticuerpo. - Google Patents

Método para producir una proteína de fusión de anticuerpo.

Info

Publication number
MX389073B
MX389073B MX2019002252A MX2019002252A MX389073B MX 389073 B MX389073 B MX 389073B MX 2019002252 A MX2019002252 A MX 2019002252A MX 2019002252 A MX2019002252 A MX 2019002252A MX 389073 B MX389073 B MX 389073B
Authority
MX
Mexico
Prior art keywords
fusion protein
producing
column chromatography
antibody
fusing
Prior art date
Application number
MX2019002252A
Other languages
English (en)
Spanish (es)
Other versions
MX2019002252A (es
Inventor
Hiroyuki Sonoda
Miroslav Matev
Shinji Kakimoto
Tsuyoshi Fukui
Yukichi Hatano
Yuri Koshimura
Original Assignee
Japan Chem Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Chem Res filed Critical Japan Chem Res
Publication of MX2019002252A publication Critical patent/MX2019002252A/es
Publication of MX389073B publication Critical patent/MX389073B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2019002252A 2016-08-25 2017-08-25 Método para producir una proteína de fusión de anticuerpo. MX389073B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016164901 2016-08-25
PCT/JP2017/030470 WO2018038243A1 (ja) 2016-08-25 2017-08-25 抗体融合蛋白質の製造方法

Publications (2)

Publication Number Publication Date
MX2019002252A MX2019002252A (es) 2019-07-04
MX389073B true MX389073B (es) 2025-03-20

Family

ID=61246169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002252A MX389073B (es) 2016-08-25 2017-08-25 Método para producir una proteína de fusión de anticuerpo.

Country Status (10)

Country Link
US (1) US11512135B2 (cg-RX-API-DMAC7.html)
EP (1) EP3505538B1 (cg-RX-API-DMAC7.html)
JP (2) JP6993814B2 (cg-RX-API-DMAC7.html)
KR (1) KR102318480B1 (cg-RX-API-DMAC7.html)
CN (1) CN109641971B (cg-RX-API-DMAC7.html)
AU (1) AU2017316955B2 (cg-RX-API-DMAC7.html)
CA (1) CA3034589A1 (cg-RX-API-DMAC7.html)
MX (1) MX389073B (cg-RX-API-DMAC7.html)
SG (1) SG11201901495YA (cg-RX-API-DMAC7.html)
WO (1) WO2018038243A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
TWI791006B (zh) 2016-12-26 2023-02-01 日商Jcr製藥股份有限公司 包含bdnf之融合蛋白質
WO2019049967A1 (ja) * 2017-09-07 2019-03-14 Jcrファーマ株式会社 水性医薬組成物
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
CN111683972A (zh) * 2018-02-05 2020-09-18 Jcr制药股份有限公司 用于将药剂递送至肌肉的方法
EP3560945A1 (en) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
JP6951051B2 (ja) * 2018-05-24 2021-10-20 HOYA Technosurgical株式会社 吸着剤の生産方法
KR102692543B1 (ko) * 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
JP2024500511A (ja) * 2020-12-23 2024-01-09 広東菲鵬制▲薬▼股▲ふん▼有限公司 抗pd-l1抗体及びその使用
JP2022108271A (ja) * 2021-01-12 2022-07-25 Jcrファーマ株式会社 リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子
MA71665A (fr) * 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
BR112023018268A2 (pt) 2021-03-09 2023-10-31 Japan Chem Res Método para produzir uma proteína de fusão
EP4455290A4 (en) * 2021-12-28 2025-11-26 Japan Chem Res Fusion protein of an anti-transferrin receptor antibody and a bioactive protein for safe gene therapy
WO2024010067A1 (ja) * 2022-07-08 2024-01-11 Jcrファーマ株式会社 中枢神経系疾患の治療のための、核酸分子、ベクター、組換え細胞及び薬剤
TW202542190A (zh) 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004271200A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2591813A1 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
JP5065391B2 (ja) 2006-12-06 2012-10-31 日本ケミカルリサーチ株式会社 ヒトエリスロポエチンの製造方法
EP2114999A2 (en) * 2006-12-12 2009-11-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
JP2009273427A (ja) 2008-05-16 2009-11-26 Jcr Pharmaceuticals Co Ltd 組換え体ヒトfshの製造方法
EP2350130B1 (en) * 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20140335163A1 (en) * 2011-12-01 2014-11-13 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6616189B2 (ja) * 2013-12-25 2019-12-04 Jcrファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
JP6071018B2 (ja) 2014-10-31 2017-02-01 Jcrファーマ株式会社 組換えヒトDNaseIの製造方法
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins

Also Published As

Publication number Publication date
CA3034589A1 (en) 2018-03-01
KR102318480B1 (ko) 2021-10-28
JP7232889B2 (ja) 2023-03-03
BR112019003622A2 (pt) 2019-05-21
AU2017316955B2 (en) 2022-03-03
WO2018038243A1 (ja) 2018-03-01
US11512135B2 (en) 2022-11-29
EP3505538B1 (en) 2024-05-01
JP6993814B2 (ja) 2022-01-14
MX2019002252A (es) 2019-07-04
SG11201901495YA (en) 2019-03-28
KR20190040040A (ko) 2019-04-16
JP2018033454A (ja) 2018-03-08
EP3505538A1 (en) 2019-07-03
JP2022028959A (ja) 2022-02-16
EP3505538A4 (en) 2020-03-18
US20190225700A1 (en) 2019-07-25
CN109641971A (zh) 2019-04-16
AU2017316955A1 (en) 2019-03-21
CN109641971B (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
SG11201901495YA (en) Method for producing antibody fusion protein
WO2019126634A3 (en) Targeted integration of nucleic acids
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
EP3539982A3 (en) Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
ZA202306500B (en) Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
MY181513A (en) Cell culture compositions and methods for polypeptide production
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
EA201492177A1 (ru) Очистка идуронат-2-сульфатазы
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
MA40021A (fr) Processus de culture cellulaire destiné à produire une protéine
BR112016012229A2 (pt) métodos de produção de polipeptídeos
MX2023010523A (es) Metodo para producir una proteina de fusion de anticuerpo-enzima lisosomica.
AR118898A1 (es) Dominios variantes para multimerizar proteínas y su separación
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX389841B (es) Proteinas inmovilizadas y uso de las mismas.
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
ZA200901825B (en) Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
MX395311B (es) Metodo para producir factor de crecimiento de hepatocitos (hgf) activo.
EA200900984A1 (ru) Улучшение клеточного роста